James Segerson
Internal Medicine · Dearborn, MINPI 1467480186
Payments from drug & device makers
Across 151 payments — averaging $13.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$312
- Novo Nordisk$262
- Lilly USA, LLC$251
- AbbVie$144
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
- E.r. Squibb & Sons, L.L.C.$119
- plus $789 from 20 others
What the payments were for
- Food & beverage$2,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 35 | $312 |
| Novo Nordisk | 22 | $262 |
| Lilly USA, LLC | 17 | $251 |
| AbbVie | 8 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $137 |
| E.r. Squibb & Sons, L.L.C. | 7 | $119 |
| Bayer | 6 | $109 |
| Amgen | 6 | $103 |
| GSK | 7 | $98 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| AstraZeneca | 5 | $67 |
| Boehringer Ingelheim | 3 | $55 |
| Pfizer | 4 | $54 |
| Merck | 3 | $41 |
| Novartis | 2 | $26 |
| Dexcom, Inc. | 2 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Corium, LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Bioventus LLC | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,014 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $16,464 |
| OzempicSemaglutide | 11 | $9,186 |
| Atorvastatin Calcium | 43 | $667 |
| Metoprolol Succinate | 38 | $663 |
| Omeprazole | 29 | $654 |
| Levothyroxine Sodium | 51 | $625 |
| Pravastatin Sodium | 19 | $562 |
| Famotidine | 18 | $422 |
| Nortriptyline Hcl | 12 | $403 |
| Rosuvastatin Calcium | 25 | $386 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $362 |
| Losartan Potassium | 20 | $356 |
| Lisinopril | 35 | $321 |
| Bupropion XlBupropion Hcl | 11 | $287 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $16,46416 claims |
| Novo NordiskOzempic | $262 | $9,18611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Dearborn
- Abdulhassan SaadDearborn$11.5M
- Ali HazimehDearborn$1.5M
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.